AbbVie (ABBV) Wednesday announced positive topline results from the first of two pivotal studies of the Phase 3 UP-AA clinical program evaluating upadacitinib in adult and adolescent patients with severe alopecia areata (AA).
In study 2 of the Phase 3 UP-AA clinical program, upadacitinib achieved primary goal by reaching 80% or more scalp hair coverage at week 24, compared to 3.4% of patients receiving placebo.
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study.
Results from the study 1 of the program are expected in the third quarter of this year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.